Successful executive-level investor relations / corporate communications / external communications / public relations professional with 30 years of communications and scientific experience in small, global mid-cap and large cap bio/pharma. Most recently served on the G1 Therapeutics (GTHX; acquired by Pharmcosmos A/S in September 2024) Executive Team as vice president of investor relations and corporate communications, with a history of building and developing award-winning global comms programs, including winning IR Magazine’s 2013 ‘IR Professional of the Year – Small Cap’ and ‘Grand Prix, Best Overall Investor Relations Program – Small Cap' awards at ViroPharma.Before joining G1, Roberts helped lead Zynerba as Vice President, Investor Relations and Corporate Communication with responsibility for the company's investor communications strategies and broad communications programming. He joined Zynerba from Adaptimmune Therapeutics, where he served as Vice President, Investor Relations (April 2015-May 2017) and helped lead their IPO. Prior, he spent 10 years at ViroPharma (acquired by Shire in January 2014), a biotechnology company routinely recognized for excellence in investor relations and communications, culminating in his tenure as vice president, corporate communications. Mr. Roberts began his professional career at MedImmune, Inc. (acquired by AstraZeneca in 2007) in 1992. He spent 12 years with the company, transitioning from his initial role as a molecular microbiology research scientist into investor relations in 1997. Specialization: Strong scientific & financial acumen; IR/comms experience in areas including rare diseases; infectious, respiratory, and transplant diseases; and cancer. Leader in communicating transformative deals. Has built global public, advocacy and investor relations programs and teams. Disclosure committee member with knowledge of regulatory/legal issues facing IR professionals. Efficient at solving for complex business problems, improving processes, departmental leadership and team building.